Artiva Biotherapeutics (ARTV) Equity Average (2023 - 2025)
Artiva Biotherapeutics (ARTV) has disclosed Equity Average for 3 consecutive years, with $119.6 million as the latest value for Q4 2025.
- For Q4 2025, Equity Average fell 38.29% year-over-year to $119.6 million; the TTM value through Dec 2025 reached $119.6 million, down 38.29%, while the annual FY2025 figure was $148.3 million, 1104.46% up from the prior year.
- Equity Average hit $119.6 million in Q4 2025 for Artiva Biotherapeutics, down from $139.1 million in the prior quarter.
- Across five years, Equity Average topped out at $193.8 million in Q4 2024 and bottomed at -$182.9 million in Q2 2024.
- Average Equity Average over 3 years is $12.8 million, with a median of $62.3 million recorded in 2024.
- On a YoY basis, Equity Average climbed as much as 2711.04% in 2025 and fell as far as 38.29% in 2025.
- Artiva Biotherapeutics' Equity Average stood at -$156.7 million in 2023, then skyrocketed by 223.66% to $193.8 million in 2024, then tumbled by 38.29% to $119.6 million in 2025.
- According to Business Quant data, Equity Average over the past three periods came in at $119.6 million, $139.1 million, and $158.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.